Biotech software alternatives, compared with AI
Four searches bring most people here: Benchling alternatives, Veeva Vault alternatives, Smartsheet alternatives, Glean alternatives. In three of those four cases the honest answer is that the incumbent is doing its job and the thing you are missing is somewhere else entirely.
People do not search for alternatives because a product broke. They search because a product is doing what it was built to do and something they care about still is not happening. The lab notebook records the experiment perfectly and nobody knows what the tox vendor promised on Tuesday's call. The quality system controls the document and the obligation with a sixty-day notice period sits in a signed PDF nobody has read since. The tracker has a beautiful Gantt and the row that moved the critical path was updated eleven days late.
So this set of pages is arranged around a single question: what is the actual gap, and is it a gap the product you are unhappy with was ever supposed to fill?
The four incumbents, and what each one is genuinely good at
| Product | The job it does | What it was never built to hold |
|---|---|---|
| Benchling | The bench. Experiments, registry, sequences, inventory, sample and test lifecycle, audit trail. In 2025 and 2026 it added an AI layer aimed squarely at science: agents, a model hub, instrument automation. | The company around the bench. Its published product line is science-facing, not partner, vendor and commitment-facing. |
| Veeva Vault | Regulated documents and compliance workflow, at very large scale. Quality, validation, training, regulatory, safety, commercial content, all on one platform, with AI agents in production since December 2025. | The pre-regulated middle of a small company: the obligations, the meeting decisions, the vendor promises that never become a controlled document. |
| Smartsheet | Collaborative work management. Timeline, grid, card, Gantt and calendar views over a sheet, plus automated approvals, notifications and dashboards for a team that shares the work. | Anything nobody typed in. A row is exactly as current as the last person who updated it. |
| Glean | Search and action across the apps a company already runs, with source permissions inherited, plus agents that can trigger work in connected systems. | Facts that live in no connected system at all, which in a small biotech is most of them. |
Read that third column again, because it is the same column four times. Every one of these products assumes that somebody, somewhere, has already put the fact into a system. That assumption is correct at four hundred people. At thirty it is the whole problem.
Start with the one you searched for
Each page below concedes what the incumbent does well, in specifics, then draws the boundary. Two of them end by telling you to keep what you have.
- Benchling alternatives: what AI changes for a small biotech. Short version: an electronic lab notebook is not the thing this replaces, and if you are shopping for one, shop for one. The related question of whether to build or buy lab notebook software is a different decision again.
- Veeva Vault alternatives for a 30-person biopharma. Short version: if the document sits inside a validated process, buy the validated system.
- Smartsheet alternatives and AI program tracking for biotech. Short version: the tool is not the problem, the typing is.
- Glean alternatives: AI search against an AI company brain. Short version: search is a layer over records you already keep somewhere else.
What sits on the other side of every one of these comparisons is a single-seat system installed for one person on their own machine, in plain files they own: one install, one owner, one mail identity, which is a genuine limitation and not a design flourish. It reads the mail and the meeting transcripts that person is already in, files each item to the right program or partner, updates the record when a fact changes, and keeps a running list of what they owe and what they are owed. Nothing outbound is ever sent without them approving it.
Here is the drug development version of the gap, which is the only version that matters. On a Thursday the monthly program review runs for an hour, and halfway through it the nonclinical lead reads out the fourteen-day tox result: a liver enzyme rise at the top dose, which reviewers will want reversibility data on. The review lands on adding a recovery arm to the GLP study, and on pausing the second program's dosing-room booking to free the time for it. That one decision changes the study scope, changes the second program's status, and creates something to settle with the vendor before the draft report date can be held. In most thirty-person companies it lands in one head and one set of scribbled notes. It is not in the notebook, because a decision to change a study's scope is not an experiment. It is not in the quality system, because it is not a controlled document. It is not in the tracker, because nobody typed it. And search cannot find it, because it was never written down anywhere a search could reach.
That is the space these pages are about, and it is the space none of the four incumbents was built for. Two more sit alongside them for people comparing general tools rather than category incumbents: Notion for biotech, and what ChatGPT cannot keep track of. If the shortlist question turns out to be whether to build the missing piece or buy it, that is the build vs buy software decision.
One decision, landing in every record it touches
An hour of review transcript goes in, and a real running app writes out the change to the GLP study scope, the second program's paused dosing-room booking, and the point to settle with the vendor before the draft report date can hold. The demo follows a single decision through all of it.
See the demo